H.I.G. Capital Acquires a Majority Stake in Santa Lucia Pharma Apps
5.7.2017 21:17 | Business Wire
H.I.G. Europe (“H.I.G.”), the European arm of global private equity firm H.I.G. Capital, announces the acquisition by an affiliate of a control stake in Santa Lucia Pharma Apps (“SLPA”), one of the leading Italian providers of advanced services to hospitals.
SLPA offers integrated turn-key solutions to hospitals for the traceability and management of unit dose drugs and medical devices. SLPA solutions, which include proprietary software, patented robotic technologies and specialist support services, enable drugs and medical devices management from digital prescription to automated personalized unit dose treatment, up to software controlled administration to patients. Complete traceability of medications and medical devices allows significant reduction in errors in therapy management and in related waste, resulting in material savings for hospitals in terms of reduced drug spending and clinical risk.
Based in Piacenza (60km from Milan, Italy), SLPA currently manages and delivers medicines to over 10,000 beds in 25 Italian hospitals, including some major university hospitals and highly respected and innovative centers. Some healthcare facilities that availed themselves of SLPA's services have received international awards, such as the “Joint Commission International”, for the achievement of significant economic and clinical benefits in terms of therapy adequacy, patient safety and optimal use of resources.
Sergio Giglio, Chairman of SLPA, commented: “We are delighted to announce the investment by H.I.G., which represents a turning point for our company. On the basis of our strong track record in Italy, we have decided to accelerate our expansion strategy in Europe, backed by an experienced global investor that will support our strategy and will help us to spread our state-of-the-art products and services internationally”.
Raffaele Legnani, Managing Director at H.I.G. in Italy, added “SLPA has achieved a leading position in Italy and has excellent growth prospects at international level. H.I.G. is pleased to team-up with SLPA and its management team and will provide them with the resources as well as the experience and network to support the internationalization process of the company”.
SLPA is one of the leading Italian providers of advanced services to hospitals, offering integrated turn-key solutions to hospitals for the traceability and management of unit dose drugs and medical devices. SLPA solutions, which include proprietary software, patented robotic technologies and specialist support services, enable drugs and medical devices management from digital prescription to automated personalized unit dose treatment, up to software controlled administration to patients. Based in Piacenza (60km from Milan, Italy), SLPA currently manages and delivers medicines to over 10,000 beds in 25 Italian hospitals, including some major university hospitals and highly respected and innovative centers.
About H.I.G. Capital
H.I.G. is a leading global private equity and alternative assets investment firm with more than €20 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and Mexico City, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/ value-added approach:
1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
Since its founding in 1993, H.I.G. has invested in and managed more than 200 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of €28 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.
* Based on total capital commitments managed by H.I.G. Capital and affiliates.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 21:33 | Tiedote
The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 15:09 | Tiedote
Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 14:26 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s
Schlumberger Announces Second-Quarter 2017 Results21.7.2017 14:00 | Tiedote
Schlumberger Limited (NYSE:SLB) today reported results for the second quarter of 2017. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2017 Mar. 31, 2017 Jun. 30, 2016
NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 10:00 | Tiedote
NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve
Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 08:00 | Tiedote
Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme